Inhaled resveratrol treatments slow ageing-related degenerative changes in mouse lung

Thorax

Volumn 72, Issue 5, 2017, Pages 451-459

  Navarro, Sonia ^a,b   Reddy, Raghava ^a   Lee, Jooeun ^a   Warburton, David ^a   Driscoll, Barbara ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; RESVERATROL; SIRTUIN 1; TELOMERASE; ANTIOXIDANT; STILBENE DERIVATIVE;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE CONTROL; DNA DAMAGE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INACTIVATION; GENE EXPRESSION; LUNG ALVEOLUS EPITHELIUM CELL; LUNG COMPLIANCE; LUNG DISEASE; LUNG FUNCTION TEST; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; TUNEL ASSAY; WESTERN BLOTTING;

ADMINISTRATION, INHALATION; AGING; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; DNA DAMAGE; IN SITU NICK-END LABELING; LUNG; MICE; MICE, INBRED C57BL; RESPIRATORY FUNCTION TESTS; STILBENES;

EID: 85009452958     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2016-208964     Document Type: Article

References (40)

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1:1645-8.
2. Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Interv Aging 2006;1:253-60.
3. Wahba WM. Influence of aging on lung function-clinical significance of changes from age twenty. Anesth Analg 1983;62:764-76.
4. Imai K, Mercer BA, Schulman LL, et al. Correlation of lung surface area to apoptosis and proliferation in human emphysema. Eur Respir J 2005;25: 250-8.
5. Lowery EM, Brubaker AL, Kuhlmann E, et al. The aging lung. Clin Interv Aging 2013;8:1489-96.
6. Thannickal VJ, Murthy M, Balch WE, et al. Blue journal conference. Aging and susceptibility to lung disease. Am J Resp Crit Care 2015;191:261-9.
7. Yokohori N, Aoshiba K, Nagai A, et al. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 2004;125:626-32.
8. Papaioannou AI, Rossios C, Kostikas K, et al. Can we delay the accelerated lung aging in COPD? Anti-aging molecules and interventions. Curr Drug Targets 2013;14:149-57.
9. Schouten LRA, Schultz MJ, van Kaam AH, et al. Association between maturation and aging and pulmonary responses in animal models of lung injury: a systematic review. Anesthesiology 2015;123:389-408.
10. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997;91:25-34.
11. Alder JK, Guo N, Kembou F, et al. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med 2011;184:904-12.
12. Barkauskas CE, Cronce MJ, Rackley CR, et al. Type 2 alveolar cells are stem cells in adult lung. J Clin Invest 2013;123:3025-36.
13. Jackson SR, Lee J, Reddy R, et al. Partial pneumonectomy of telomerase null mice carrying shortened telomeres initiates cell growth arrest resulting in a limited compensatory growth response. Am J Physiol Lung Cell Mol Physiol 2011;300: L898-909.
14. Lee J, Reddy R, Barsky L, et al. Lung alveolar integrity is compromised by telomere shortening in telomerase-null mice. Am J Physiol Lung Cell Mol Physiol 2009;296: L57-70.
15. Alder JK, Barkauskas CE, Limjunyawong N, et al. Telomere dysfunction causes alveolar stem cell failure. Proc Natl Acad Sci USA 2015;112: 5099-104.
16. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008;7:1020-35.
17. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191-6.
18. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Bio 2012;13:225-38.
19. Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrin Met 2014;25:138-45.
20. Hori YS, Kuno A, Hosoda R, et al. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS ONE 2013;8:e73875.
21. Lee JT, Gu W. SIRT1: regulator of p53 deacetylation. Genes Cancer 2013;4:112-17.
22. Imboden M, Schwartz J, Schindler C, et al. Decreased PM10 exposure attenuates age-related lung function decline: genetic variants in p53, p21, and CCND1 modify this effect. Environ Health Persp 2009;117:1420-7.
23. Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012;15:675-90.
24. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor γ coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 2006;27:728-35.
25. Rajendrasozhan S, Yang SR, Kinnula VL, et al. SIRT1, an anti-inflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:861-70.
26. Timmers S, Auwerx J, Schrauwen P. The journey of resveratrol from yeast to human. Aging (Albany NY) 2012;4:146-58.
27. Chung SW, Yao HW, Caito S, et al. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 2010;501:79-90.
28. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5:493-506.
29. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127:1109-22.
30. Feige JN, Lagouge M, Canto C, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2008;8:347-58.
31. Hubbard BP, Sinclair DA. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 2014;35:146-54.
32. Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012;148:421-33.
33. Van Houten B, Woshner V, Santos JH. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair (Amst) 2006;5:145-52.
34. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 2008;88:611-38.
35. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001;8:781-94.
36. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 2001;107:137-48.
37. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-59.
38. Reddy R, Buckley S, Doerken M, et al. Isolation of a putative progenitor subpopulation of alveolar epithelial type 2 cells. Am J Physiol Lung Cell Mol Physiol 2004;286:L658-67.
39. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-42.
40. Cao Q, Jing C, Tang X, et al. Protective effect of resveratrol on acute lung injury induced by lipopolysaccharide in mice. Anat Rec (Hoboken) 2011;294:527-32.